ESTRO 2024 - Abstract Book

S549

Clinical - Breast

ESTRO 2024

drugs able to ensure extracranial disease control and prolong pts survival. Further analyses on the appropriate timing for integrated approaches, as well as prospective data on larger sample sizes, are encouraged.

Keywords: Brain metastases, Breast Cancer, Radiotherapy

1486

Digital Poster

Male breast cancer in Brazil: a large population-based study

Ridania O Frederice 1 , Allan A.L Pereira 2 , Gustavo V. Arruda 3 , Andre G Gouveia 4 , Felipe E.M. de Andrade 1 , Lincon J. Mori 1 , Rudinei D.M. Linck 5 , Andrea K. Shiamada 5 , Samir A. Hanna 6 , Fabio Y. de Moraes 7 , Gustavo N. Marta 6 1 Hospital Sírio-Libanês, Breast Surgery, Sao Paulo, Brazil. 2 Hospital Sírio-Libanês, Clinical Oncology, Brasilia, Brazil. 3 University of São Paulo, Department of Medical Imaging, Hematology and Oncology, Ribeirão Preto, Brazil. 4 • Juravinski Cancer Centre, Department of Oncology, Division of Radiation Oncology, Hamilton, Canada. 5 Hospital Sírio-Libanês, Clinical Oncology, Sao Paulo, Brazil. 6 Hospital Sírio-Libanês, Department of Radiation Oncology, Sao Paulo, Brazil. 7 Queen's University, • Department of Oncology, Kingston, Canada

Purpose/Objective:

This study evaluated the clinicopathological characteristics, treatment trends and overall survival (OS) in male breast cancer (MBC) in Sao Paulo State of Brazil.

Material/Methods:

Men diagnosed with invasive breast cancer between January 2000 and June 2020 were identified from Fundação Oncocentro de Sao Paulo database. Patients were described according to age, education level, clinical stage, treatment modalities, and medical practice. Categorical variables were described as percentages and frequencies. Demographic, treatment factors, and OS were associated using a Cox proportional hazard regression model while accounting for different lengths of participant follow-up. The Kaplan-Meier curves were used to display survival curves.

Results:

A total of 907 MBC patients were included. The age distribution at diagnosis was <51 years, 51-70 years, and >70 years in 21.5%, 51.5% and 27.0% of patients, respectively. The proportions of stages I, II, III, and IV were 19.5%, 36.6%, 31.5% and 12.3%. For each stage I, II, III, and IV, 5- and 10-years OS were 87.9% and 77.8%, 79.9% and 58.9%, 51.6% and 24.5%, 20.0% and 5.6%, respectively. In the multivariable analysis adjusted for practice (public or private), education (low or medium/high), age, stage at diagnosis, and treatment modalities, the significant independent predictor for OS was stage at diagnosis.